Summary of Apex Medical Conference Call Company Overview - **Company**: Apex Medical - **Industry**: Medical Technology, specifically in surgical aesthetics - **Specialization**: Helium plasma energy solutions for minimally invasive cosmetic and surgical procedures [2][3] Core Insights and Arguments - **Market Leadership**: Apex Medical is positioned as a leader in surgical technologies for minimally invasive aesthetic procedures, particularly with their FDA-approved device, Renuvion, for treating loose and lax skin [4][5] - **Impact of GLP-1 Drugs**: The aesthetic market has significantly changed due to the introduction of GLP-1 drugs, which are projected to become a $100 billion market by 2030. Nearly 63% of GLP-1 users are new to aesthetic treatments, indicating a growing customer base for aesthetic procedures [5][6] - **Procedure Trends**: There has been a decline in liposuction procedures (down 10%), while surgical lifts have increased by over 20%. This trend aligns with the need for surgical interventions as patients lose weight and experience skin laxity [6][7] - **Patient Behavior**: 57% of patients seek treatment within six months after reaching their ideal weight, indicating a strong demand for surgical interventions post-weight loss [8][9] Financial Performance and Market Potential - **Revenue**: Apex Medical generated approximately $50 million in revenue last year, operating in a market valued at around $10 billion [11] - **Single-Use Handpieces**: The company sold 93,000 single-use handpieces, with an average selling price (ASP) of $500, marking a 14% growth in this segment [12] - **Cost Management**: The company aims to reduce operating costs to below $40 million this year, down from $53 million in 2023, to achieve profitability [25][26] Product Development and Launch - **AON Body Contouring System**: The AON system, approved in May, is set to launch commercially in September. It consolidates multiple technologies into one platform, enhancing efficiency and safety in surgical procedures [18][19] - **Ultrasonic Technology**: The AON system features advanced ultrasonic technology (LIFT technology) that improves fat emulsification speed and safety compared to existing technologies [20][21] Marketing and Consumer Engagement - **Direct-to-Consumer (DTC) Strategy**: Apex Medical is enhancing its DTC marketing for Renuvion to educate consumers about skin laxity treatment options, while focusing on B2B strategies for AON [22] - **Awards and Recognition**: Renuvion recently won the Best Minimally Invasive Skin Tightener award, highlighting its significance in the beauty market [22] Global Presence and Future Plans - **International Operations**: The company has R&D and manufacturing facilities in the U.S. and Bulgaria, with a joint venture in China, where it has recently begun commercial operations [23][24] - **Future Focus**: Apex Medical plans to expand the adoption of Renuvion and continue developing AON for international markets, emphasizing evidence-based medicine and clinical research [27][28] Additional Insights - **Surgeon Partnerships**: The company focuses on building partnerships with plastic surgeons, aiming to support their practices and improve patient outcomes [30][31] - **Market Trends**: The rise of GLP-1 drugs is expected to influence aesthetic treatment trends globally, with increasing accessibility in markets like Brazil [33]

Apyx Medical (APYX) Q2 2025 Earnings Call August 07, 2025 04:30 PM ET Speaker0Good afternoon, ladies and gentlemen, and welcome to the Apyx Medical Second Quarter twenty twenty five Earnings Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 08/07/2025. I would now like to turn the conference over to Jeremy Feffert, LifeSci Advisors.Please go ahead.Speaker1Thank you and welcome ...

Core Points - Apyx Medical Corporation granted a nonstatutory stock option to John Featherstone, Vice President of North American Sales, for 100,000 shares as an inducement for employment [1][2] - The stock option has an exercise price of $1.85, which is the closing price of Apyx Medical's common stock on the grant date [2] - The stock option vests over a four-year period, with 25% vesting on the first anniversary and the remainder vesting annually, contingent on continued employment [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co., Ltd. post-initial market clearance Founded in 2013, BCC is a leading platform company in China's medical aesthetics industry with businesses spanning medical services, supply chain and digital innovation. In medical services, BCC invests, controls, and operates over 60 medical aesthetics hospitals and clinics across 15 cities nationwide. It is the largest ...

Core Viewpoint - Apyx Medical Corporation will release its financial results for Q2 of fiscal year 2025 on August 7, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 4:30 p.m. Eastern Time on the same day [2] - Interested parties can join the call by dialing 800-717-1738 or 646-307-1865 for international callers, using access code 35370 [2] - A live webcast of the call will be available on the company's website and will be archived for future reference [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and the AYON Body Contouring System™ [3] - The company’s Helium Plasma Platform Technology is utilized in both cosmetic surgery and hospital surgical markets, providing surgeons with controlled heat to achieve desired results [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical publications, showcasing the company's commitment to clinical validation [3] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion, is pleased ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $9.4 million, a decrease of 8% compared to $10.2 million in the same period last year [4] - Advanced Energy products revenue increased by 6% to $7.9 million, reflecting stronger sales trends in the U.S. [5] - OEM segment sales decreased by 44.7% to approximately $1.2 million [16] - Gross profit for Q1 2025 decreased to $5.7 million from $5.9 million in the prior year, but gross profit margin increased to 60.1% from 58.1% [16][17] - Net loss attributable to shareholders was $4.2 million or $0.10 per share, compared to $7.6 million or $0.22 per share in the prior year [18] Business Line Data and Key Metrics Changes - Advanced Energy segment revenue increased by 5.8% to $7.9 million due to increased volume of single-use handpieces and domestic sales of new generators [15] - OEM segment sales saw a significant decline of 44.7% due to decreased sales volume to existing customers [16] - Domestic revenue decreased by 3.4% year over year to $6.7 million, while international revenue decreased by 17.7% to $2.7 million [16] Market Data and Key Metrics Changes - The company noted a stabilization in demand for capital equipment in the U.S., with year-over-year increases for two consecutive quarters [5] - The growth of GLP-1 drugs is expected to drive demand for aesthetic treatments, particularly for patients experiencing loose skin due to rapid weight loss [8] Company Strategy and Development Direction - The company is focusing on the launch of the AON body contouring platform, which integrates multiple technologies into a single device [13] - Apyx Medical aims to position the AON system in the operating rooms of surgeons, enhancing its market share in aesthetic surgery [14] - The company is committed to maintaining expense control while supporting the AON launch, viewing it as a significant differentiator in the market [33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged persistent macroeconomic headwinds affecting the global aesthetic space but remains optimistic about the growth potential driven by GLP-1s [7][8] - The company expects to return to more normalized cash burn for the remainder of 2025, projecting cash management will yield positive results into 2027 [19] - Revenue guidance for 2025 is set between $47.6 million and $49 million, with expectations for Advanced Energy revenue to increase [20] Other Important Information - Renuvion was awarded the 2025 New Beauty Award for Best Minimally Invasive Skin Tightener, highlighting its market position [11] - The company has implemented significant cost-cutting measures and a restructuring program to reduce cash burn and improve operational efficiency [6] Q&A Session Summary Question: Progress on AON platform and customer enrollment - Management indicated they are not ready to comment on the AON pipeline yet but noted excitement in the marketplace regarding upgrades to the APYX-ONE console [22][23] Question: Demand for APYX-ONE upgrades - Management confirmed they are seeing positive demand for upgrades to the APYX-ONE console as customers prepare for AON [24][25] Question: Tariff impacts on margins - Management stated they expect gross margins to remain around 60% for the year, indicating minimal impact from tariffs at this point [32] Question: Investments to support AON launch - Management emphasized that while controlling expenses is crucial, investments to support the AON launch will not be compromised [33]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $9.4 million, a decrease of 8% compared to $10.2 million in Q1 2024 [5][16] - Gross profit for Q1 2025 decreased to $5.7 million from $5.9 million in the prior year, with a gross profit margin of 60.1%, up from 58.1% [17][18] - Net loss attributable to shareholders was $4.2 million or $0.10 per share, compared to $7.6 million or $0.22 per share in the prior year [19] Business Line Data and Key Metrics Changes - Advanced Energy segment revenue increased by 6% to $7.9 million, driven by stronger sales of single-use handpieces in the U.S. [6][16] - OEM segment sales decreased by 44.7% to approximately $1.2 million, attributed to lower sales volume to existing customers [17] Market Data and Key Metrics Changes - Domestic revenue decreased by 3.4% year-over-year to $6.7 million, while international revenue decreased by 17.7% to $2.7 million [17] - The company noted a stabilization in demand for capital equipment in the U.S., with year-over-year increases for two consecutive quarters [6] Company Strategy and Development Direction - The company is focusing on the Renuvion offering as a key product for addressing loose and lax skin, particularly for patients experiencing rapid weight loss due to GLP-1 drugs [10][11] - AON body contouring platform is expected to differentiate the company in the market, with a planned launch in the second half of 2025 pending FDA clearance [14][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged persistent macroeconomic headwinds but expressed optimism about the growth potential from the GLP-1 market [7][9] - The company expects to return to more normalized cash burn for the remainder of 2025, projecting cash flow into 2027 [20] Other Important Information - The company implemented significant cost-cutting measures, resulting in a decrease in operating expenses to $8.7 million from $12.6 million in the prior year [19] - Renuvion won the 2025 New Beauty Award for Best Minimally Invasive Skin Tightener, highlighting its market recognition [12] Q&A Session Summary Question: Progress on AON platform and customer enrollment - Management indicated they are not commenting on the AON pipeline yet but noted excitement in the marketplace regarding upgrades to the APYX-one console [24][25] Question: Demand for APYX One console upgrades - Management confirmed they are seeing increased demand for the APYX One console as customers prepare for AON [26][27] Question: Tariff impacts and supply chain - Management stated they have manufacturing flexibility between the U.S. and Bulgaria to mitigate potential tariff impacts [30][31] Question: Margin impact from tariffs - Management expects gross margins to remain around 60% for the year, indicating minimal impact from current tariff considerations [34] Question: Investments to support AON launch - Management emphasized that while controlling expenses is important, investments to support the AON launch will not be compromised [35]

Core Insights - Apyx Medical Corporation reported a total revenue of $9.4 million for Q1 2025, a decrease from $10.2 million in the same period last year, primarily due to a significant drop in OEM revenue [5][7] - The Advanced Energy segment saw a 6% increase in revenue to $7.9 million, driven by strong sales of generator units and single-use handpieces [4][5] - The company is preparing to launch the AYON Body Contouring System in the second half of 2025, pending FDA clearance, which is expected to enhance its market position in surgical aesthetics [3][5] Financial Performance - Total revenue decreased by 8% year-over-year, with Advanced Energy revenue increasing by 6% while OEM revenue fell by 45% [5][7] - Gross profit for Q1 2025 was $5.7 million, with a gross profit margin of 60%, up from 58% in the prior year [8] - Operating expenses decreased significantly by $3.8 million to $8.7 million, reflecting cost-cutting measures implemented in the previous quarter [9] Loss and Adjusted EBITDA - The net loss attributable to stockholders decreased by 45% to $4.2 million, or $0.10 per share, compared to a loss of $7.6 million, or $0.22 per share, in Q1 2024 [11][20] - Adjusted EBITDA loss improved to $2.4 million from $5.3 million in the prior year, indicating better operational efficiency [11][26] Market Position and Strategy - Renuvion, the company's flagship product, was awarded the 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener," highlighting its growing recognition in the market [5][11] - The company aims to capitalize on the increasing demand for aesthetic procedures, particularly among patients using GLP-1 drugs for weight loss [3][5] - Apyx Medical's management expressed confidence in the company's path to profitability following recent restructuring and cost management efforts [6][9]

Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly in the cosmetic surgery market with its Helium Plasma Platform Technology products marketed as Renuvion and J-Plasma [5] - Renuvion is the only FDA-cleared device for use after liposuction, addressing issues related to loose skin with more than 90 evidence-based clinical publications supporting its effectiveness [3][5] - The company aims to elevate people's lives through innovative products that provide controlled heat to tissue for desired surgical results [5] Marketing Strategy - Dolores Catania has been appointed as the Chief of Confidence for Apyx Medical's Renew You consumer marketing campaign, focusing on body contouring and the challenges of loose skin [1][2] - Catania will be featured in various marketing initiatives across multiple platforms, including social media, public relations, live engagements, and physician events [4] - The campaign emphasizes the emotional and physical benefits of Renuvion treatments, aiming to empower consumers in their personal transformations [3][4] Industry Position - Renuvion is recognized as the 1 body contouring technology trusted by doctors to effectively address loose skin challenges [3][6] - An independent survey indicated that 4 out of 5 board-certified or eligible cosmetic and plastic surgeons in the US agree on the effectiveness of Renuvion [6]